恩替卡韦治疗慢性乙型重型肝炎疗效观察  

Study of entecavir in treating chronic severe hepatitis B patients

作　　者：杨澍[1] 徐强胜[1] 王雪刚[1] 彭秋燕[1] 洪婉媚 

机构地区：[1]深圳市宝安人民医院暨第八人民医院感染病科,广东深圳518101

出　　处：《中国医院药学杂志》2009年第6期473-475,共3页Chinese Journal of Hospital Pharmacy

基　　金：2006年宝安科技局立项(编号:2005180)

摘　　要：目的:观察恩替卡韦(ETV)对慢性重症肝炎的疗效和安全性。方法:对56例早中期慢性乙型重型肝炎患者分为对照组(28例)和治疗组(28例),分别采用综合治疗和加用ETV的治疗(0.5mg,qd),定期观察肝功能(TB、ALT、AST、ALB、PT),乙肝"两对半"及HBVDNA,以及患者的治愈、好转率,进行统计分析。结果:ETV降低HBVDNA较明显,第3周始对改善肝功能有显著性差异,但短期6周内患者的治愈率好转率差异皆不具有显著性。结论:ETV可以改善肝功能,但短期1～2周疗效果差异无显著性,3～4周开始两组间差异有显著性及提示有一定的救治意义,ETV对重症肝炎治疗有显著疗效。OBJECTIVE To study the effect and safety of antiviral treatment for chronic hepatitis B Patients with entecavir. METHODS 56 patients which was the early/middle severe hepatitis B patients were 1 ： 1 to receive either ETV （0. 5 mg,qd） as treatment group or Comprehensive treatment as the control group. Measurements of liver function （TB, ALT, AST, ALB and PT）,Serum Markers of Hepatitis B （ HBsAg, HBsAb, HBeAg, HBeAh and HBcAb）, and serum HBVDNA by PCR assay were wnducted. Statistic analyses for the clinical cure rate and improvement proportion were made. RESULTS The effective function was reducing serum HBV DNA levels. The difference of statistic analysis was observed about the liver function im provement at week 3. But about the clinical cure rate and improvement proportion, no difference at week 6. CONCLUSION The liver function could be improved with antiviral treatment of entecavir. At first 1- 2 weeks, the effect is no difference be tween the two groups. But at week 3, week 4, it turns to obviously statistic difference and having the treatment significance. The effect of antiviral treatment with entecavir is measurably in chronic severe hepatitis B patient.

关 键 词：恩替卡韦 慢性重型肝炎 乙型肝炎病毒 抗病毒治疗 

分 类 号：R969[医药卫生—药理学]